Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Dupilumab is prescribed for treating moderate-to-severe atopic dermatitis in adult patients who do not respond to topical treatments or cannot tolerate standard therapies. It acts as an ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Researchers compiled findings from seven studies demonstrating the real-world utility of tralokinumab for atopic dermatitis ... biologic treatments including dupilumab, abrocitinib and ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting ... across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard.

including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... s blockbuster AD therapy Dupixent (dupilumab) – while blocking IL-31 may tackle other ...

The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms. 2024 was a big year for the atopic dermatitis (AD) ...